by Teymour Boutros-Ghali and Felicia Hsu
Welcome to Just BOLD Enough, where we explore BOLD Capital Partner’s mission to invest in healthcare and technology companies that disrupt industries and uplift humanity. We’ll share expert insights and have engaging discussions on impact, investment philosophy, and our perspective on the very issues shaping our world. Get ready to embrace innovation with purpose – this is Just BOLD Enough. To learn more, visit: https://boldcapitalpartners.com/
Language
🇺🇲
Publishing Since
2/22/2024
Pitch yourself as a guest, propose sponsorships, or reach out directly to the host.
June 6, 2024
<p>The conversation explores the topic of humanoid robots and how science fiction is becoming a reality. The principal themes include the advancements in language and visual models, the reduction in mechanical costs, the importance of humanoid shape, the near-term markets for humanoid robots, and the companies involved in this field.<br/><br/>Story Notes:<br/><br/></p><ul><li>Advancements in Language and Visual Models</li><li>The Importance of Humanoid Shape</li><li>Near-Term Markets for Humanoid Robots</li><li>Figure AI: Leading the Way in Humanoid Robotics</li></ul><p>To learn more, visit:<br/><a href='https://boldcapitalpartners.com/'><b>https://boldcapitalpartners.com/</b></a></p>
April 25, 2024
<p>In this episode of Just Bold Enough, Teymour and Felicia discuss an innovative biotech company, Syntis Bio, and how it will disrupt obesity treatment. Syntis has developed a gastric bypass-in-a-pill that blocks the absorption of glucose in the small intestine. This simple, yet clever solution could revolutionize the treatment of obesity and have a significant impact on the pharmaceutical industry by improving the delivery of other drugs. The team is led by experienced CEO, Rahul Dhanda, who is now leading the company into human clinical trials. The company also prioritizes health equity by aiming to disrupt the high cost of obesity treatments such as Ozempic and make it more accessible to those who need it.<br/><br/>Story Notes:<br/><br/></p><ul><li> Addressing the Obesity Challenge</li><li>Navigating the Regulatory Landscape</li><li>The Potential Impact on the Pharmaceutical Industry</li></ul><p>To learn more, visit:<br/><a href='https://boldcapitalpartners.com/'><b>https://boldcapitalpartners.com/</b></a></p>
April 11, 2024
<p>Insilico Medicine uses generative AI for drug discovery and has set the trend for AI in the pharmaceutical industry. They have developed an AI platform to identify novel targets and molecules, significantly reducing the time and cost of the drug discovery process. The company has a pipeline of novel molecules and drugs, with one asset in clinical trials for idiopathic pulmonary fibrosis (IPF). They’ve gained the trust of the pharma industry and have partnerships with big pharma and contract research organizations.<br/><br/>Story Notes:<br/><br/></p><ul><li>Introduction and Background of Insilico Medicine</li><li>Understanding Generative AI</li><li>Insilico Medicine's Approach to Drug Discovery</li><li>The Visionary Leadership of Alex Zhavoronkov</li></ul><p><br/>To learn more, visit:<br/><a href='https://boldcapitalpartners.com/'><b>https://boldcapitalpartners.com/</b></a></p>
Have a different question and can't find the answer you're looking for? Reach out to our support team by sending us an email and we'll get back to you as soon as we can.
Welcome to Just BOLD Enough, where we explore BOLD Capital Partner’s mission to invest in healthcare and technology companies that disrupt industries and uplift humanity. We’ll share expert insights and have engaging discussions on impact, investment philosophy, and our perspective on the very issues shaping our world. Get ready to embrace innovation with purpose – this is Just BOLD Enough.
To learn more, visit: https://boldcapitalpartners.com/
This podcast updates weekly.
This podcast is available on 9 platforms including Apple Podcasts, Spotify, and more. You can also use the RSS feed directly.
Information about guest appearances is not available.
Pod Engine is not affiliated with, endorsed by, or officially connected with any of the podcasts displayed on this platform. We operate independently as a podcast discovery and analytics service.
All podcast artwork, thumbnails, and content displayed on this page are the property of their respective owners and are protected by applicable copyright laws. This includes, but is not limited to, podcast cover art, episode artwork, show descriptions, episode titles, transcripts, audio snippets, and any other content originating from the podcast creators or their licensors.
We display this content under fair use principles and/or implied license for the purpose of podcast discovery, information, and commentary. We make no claim of ownership over any podcast content, artwork, or related materials shown on this platform. All trademarks, service marks, and trade names are the property of their respective owners.
While we strive to ensure all content usage is properly authorized, if you are a rights holder and believe your content is being used inappropriately or without proper authorization, please contact us immediately at hey@podengine.ai for prompt review and appropriate action, which may include content removal or proper attribution.
By accessing and using this platform, you acknowledge and agree to respect all applicable copyright laws and intellectual property rights of content owners. Any unauthorized reproduction, distribution, or commercial use of the content displayed on this platform is strictly prohibited.